Search research articles
Contact Us
Filters
Showing results (511-520 of 522) with videos related to
Page
of 53
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 8, 2025
RP1 Combined With Nivolumab in Advanced Anti-PD-1-Failed Melanoma (IGNYTE)
Michael K Wong, Mohammed M Milhem, Joseph J Sacco, et al.
Nature Medicine
|
April 24, 2025
CMV serostatus is associated with improved survival and delayed toxicity onset following anti-PD-1 checkpoint blockade
Gusztav Milotay, Martin Little, Robert A Watson, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 2, 2020
European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 2. Treatment
Alexander J Stratigos, Claus Garbe, Clio Dessinioti, et al.
Multiple Sclerosis and Related Disorders
|
November 2, 2018
Multiple sclerosis registries in Europe - An updated mapping survey
A Glaser, A Stahmann, T Meissner, et al.
Cancer Cell
|
July 11, 2023
Tumor monocyte content predicts immunochemotherapy outcomes in esophageal adenocarcinoma
Thomas M Carroll, Joseph A Chadwick, Richard P Owen, et al.
The New England Journal of Medicine
|
September 12, 2017
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
Jeffrey Weber, Mario Mandala, Michele Del Vecchio, et al.
Journal of the National Cancer Institute
|
December 5, 2013
Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial
William Greenhalf, Paula Ghaneh, John P Neoptolemos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 14, 2023
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238
James Larkin, Michele Del Vecchio, Mario Mandalá, et al.
Science Translational Medicine
|
June 20, 2020
ctDNA monitoring using patient-specific sequencing and integration of variant reads
Jonathan C M Wan, Katrin Heider, Davina Gale, et al.
Nature Communications
|
February 6, 2025
Distinct immune cell infiltration patterns in pancreatic ductal adenocarcinoma (PDAC) exhibit divergent immune cell selection and immunosuppressive mechanisms
Shivan Sivakumar, Ashwin Jainarayanan, Edward Arbe-Barnes, et al.
Page
of 53
Search research articles
Search
Showing results (511-520 of 522) with videos related to
Sort By:
Page
of 53
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 8, 2025
RP1 Combined With Nivolumab in Advanced Anti-PD-1-Failed Melanoma (IGNYTE)
Michael K Wong, Mohammed M Milhem, Joseph J Sacco, et al.
Nature Medicine
|
April 24, 2025
CMV serostatus is associated with improved survival and delayed toxicity onset following anti-PD-1 checkpoint blockade
Gusztav Milotay, Martin Little, Robert A Watson, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 2, 2020
European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 2. Treatment
Alexander J Stratigos, Claus Garbe, Clio Dessinioti, et al.
Multiple Sclerosis and Related Disorders
|
November 2, 2018
Multiple sclerosis registries in Europe - An updated mapping survey
A Glaser, A Stahmann, T Meissner, et al.
Cancer Cell
|
July 11, 2023
Tumor monocyte content predicts immunochemotherapy outcomes in esophageal adenocarcinoma
Thomas M Carroll, Joseph A Chadwick, Richard P Owen, et al.
The New England Journal of Medicine
|
September 12, 2017
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
Jeffrey Weber, Mario Mandala, Michele Del Vecchio, et al.
Journal of the National Cancer Institute
|
December 5, 2013
Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial
William Greenhalf, Paula Ghaneh, John P Neoptolemos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 14, 2023
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238
James Larkin, Michele Del Vecchio, Mario Mandalá, et al.
Science Translational Medicine
|
June 20, 2020
ctDNA monitoring using patient-specific sequencing and integration of variant reads
Jonathan C M Wan, Katrin Heider, Davina Gale, et al.
Nature Communications
|
February 6, 2025
Distinct immune cell infiltration patterns in pancreatic ductal adenocarcinoma (PDAC) exhibit divergent immune cell selection and immunosuppressive mechanisms
Shivan Sivakumar, Ashwin Jainarayanan, Edward Arbe-Barnes, et al.
Page
of 53